BDX
$154.13-2.40 (-1.53%)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...
Recent News
Is Edwards Lifesciences Corporation (EW) A Good Stock To Buy Now?
Is EW a good stock to buy? We came across a bullish thesis on Edwards Lifesciences Corporation Torre Financial Newsletter’s Substack by Federico Torre. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation’s share was trading at $83.92 as of March 16th. EW’s trailing and forward P/E were 46.17 and 28.49 respectively according to Yahoo Finance. Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in th
Should You Hold or Sell HOLX Stock as It Nears the End of Public Phase?
Hologic nears its $76 buyout price as Diagnostics faces headwinds, tariffs hurt, and the stock trades at a sector premium.
3 Reasons BDX is Risky and 1 Stock to Buy Instead
Over the last six months, BD’s shares have sunk to $160.20, producing a disappointing 14.6% loss while the S&P 500 was flat. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Assessing Becton Dickinson’s Valuation After Recent Share Weakness And Planned Business Separation
What recent returns say about Becton Dickinson (BDX) Becton Dickinson (BDX) has been under pressure, with the share price showing a 0.2% decline over the past day, about 4.6% over the past week, and roughly 9.4% over the past month. See our latest analysis for Becton Dickinson. The recent weakness is not just a short blip, with a 90 day share price return of 20.4% and an 18.3% year to date share price decline feeding into a 1 year total shareholder return of 8.2% and softer multi year...
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8% return has closely followed the S&P 500.